Hot Pursuit     02-Sep-23
Biocon acquires facility of Eywa Pharma in US for $7.7 mln
The biopharmaceutical company announced that its step-down, wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.'s oral solid dosage manufacturing facility located in Cranbury, New Jersey, U.S., effective 1 September 2023.
The facility is acquired for a total consideration of $7.7 million. As part of the acquisition, the existing workforce of the facility will transition to Biocon Generics Inc.

The company stated that the facility has a potential for capacity expansion up to 2 billion tablets/capsules per year.

Siddharth Mittal, managing director & CEO of Biocon said, “The acquisition of this US FDA approved facility, our first in the U.S., will complement Biocon's existing manufacturing capabilities and strengthen our foothold in the United States.

The acquisition will also enable us to add oral solid dosage capacitiesfor new products earlier than originally planned and ensure continuity of supply through the diversification of our manufacturing infrastructure. Our focus will be on integrating the acquired facility expeditiously and expanding our portfolio in the region.”

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company reported 30% decline in consolidated net profit to Rs 101 crore in Q1 FY24 from Rs 144 crore in Q1 FY23. Consolidated revenues for Q1 FY24 grew 59% YoY to Rs 3,516 crore.

The scrip closed 0.48% higher at Rs 260.65 on Friday, 1 September 2023.

Previous News
  Indices trade with decent gains; realty shares rallied for 5th day
 ( Market Commentary - Mid-Session 17-May-24   12:40 )
  Biocon Biologics receives EMA CHMP's positive opinion for YESAFILI®, an aflibercept biosimilar
 ( Corporate News - 24-Jul-23   09:17 )
  Biocon Ltd up for third consecutive session
 ( Hot Pursuit - 29-Sep-23   13:05 )
  Biocon gains as arm takes over Viatris' biosimilar biz in over 70 countries
 ( Hot Pursuit - 06-Jul-23   12:03 )
  Biocon Q1 PAT climbs 71% YoY to Rs 144 cr
 ( Hot Pursuit - 28-Jul-22   09:53 )
  Eris Lifesciences avails term loan of Rs 280 cr from Citi Bank
 ( Corporate News - 09-Nov-23   09:15 )
  Biocon gains after receiving MHRA UK approval for Liraglutide injection
 ( Hot Pursuit - 01-Apr-24   10:34 )
  Biocon features in S&P's Sustainability Yearbook 2024
 ( Corporate News - 20-Feb-24   12:28 )
 ( Results - Analysis 16-Feb-23   10:55 )
  Biocon Ltd spurts 0.7%, gains for fifth straight session
 ( Hot Pursuit - 03-Oct-22   13:00 )
  Biocon Ltd down for fifth straight session
 ( Hot Pursuit - 10-May-22   13:35 )
Other Stories
  Inox Green Energy board OKs fund raising proposal
  22-Jun-24   17:00
  Cipla Goa facility gets 6 USFDA observations
  22-Jun-24   16:22
  EIH CFO Kallol Kundu resigns
  22-Jun-24   14:20
  Sky Gold acquires entire stake in Starmangalsutra & Sparkling Chains
  22-Jun-24   13:31
  TVS Motor inks pact with CSC Grameen eStores for its CV range
  22-Jun-24   12:27
  Prestige Estates to raise Rs 5000 crore via QIP
  22-Jun-24   11:59
  JSW Energy arm bags LoA from SECI
  22-Jun-24   10:56
  RVNL emerges as L-1 bidder for Rs 191-cr railway project
  22-Jun-24   09:54
  Bajaj Consumer hits 52-week high as board OKs Rs 166-cr share buyback
  21-Jun-24   15:28
  GRM Overseas rallies as board OKs Rs 136-cr preferential issue
  21-Jun-24   15:19
Back Top